Would vaccination be enough to end the COVID19 crisis or is it another crisis in the making?
What do the new strains and the vaccine rollout mean for the timing to end the pandemic?.
This article updates our earlier perspectives on when the coronavirus pandemic will end. Transition toward normalcy in the United States remains most likely in the second quarter of 2021 and herd immunity in the third and fourth quarters, but the emergence of new strains and a slow start to vaccine rollout raise real risks to both timelines. We also add a perspective for the United Kingdom.
https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/when-will-the-covid-19-pandemic-end
The risks and challenges of the global COVID-19-vaccine rollout
The COVID-19 vaccines of the BioNTech and Pfizer partnership (Pfizer–BioNTech) and Moderna have received Emergency Use Authorization in Canada, the European Union, the United Kingdom, the United States, and other countries. Many frontline workers and priority population segments have received their first doses. Vaccines from AstraZeneca, Johnson & Johnson, and several other global manufacturers are also arriving (or are expected to arrive soon) and are being distributed for administration around the world. This monumental global effort has shattered the record for vaccine development: the fastest previous vaccine project, Merck’s mumps vaccine, was four and a half years in development (1963–67).
https://www.mckinsey.com/business-functions/risk/our-insights/the-risks-and-challenges-of-the-global-covid-19-vaccine-rollout
